Core Insights - The 15th annual Clarivate Pharmavision India conference will focus on improving patient outcomes and resilience in the healthcare ecosystem, taking place on September 25-26, 2024, in Ahmedabad and Hyderabad [1][2]. Industry Focus - The conference aims to address critical challenges in healthcare affordability and access, emphasizing the need for patient-centric approaches to ensure sustainable growth and competitive advantage [2]. - Industry leaders will discuss the integration of innovative strategies in R&D, generics, biosimilars, and healthcare manufacturing to foster collaboration and drive growth [3]. Key Sessions - Notable sessions include discussions on the balance between generics and innovation in Indian Pharma, the role of AI and big data in healthcare, and the integration of cell and gene therapy into clinical practice [3]. - Specific presentations will cover topics such as affordability in the global scenario and creating value for patients and stakeholders [3]. Organizational Role - Clarivate positions itself as a leader in fostering collaboration across life sciences and healthcare industries, aiming to enhance patient outcomes through impactful forums like Pharmavision India [3].

LONDON, Sept. 9, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today launched its first Pulse of the LibraryTM report. The report reveals that libraries are in the early days of Artificial Intelligence (AI) implementation. Librarians are considering applications of AI that support the library mission, particularly in enhancing content discovery and increasing efficiency for their teams. However, there are notable concerns, including a lack of AI ex ...

Developed in partnership with the research community to implement high-quality AI tools responsibly LONDON, Sept. 4, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released the Web of Science™ Research Assistant. The new generative AIpowered tool helps researchers find key papers faster, handle complex research tasks and visualize connections. The chat interface combined with the Web of Science knowledge graph allows researchers to get more ou ...

LONDON, Aug. 20, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, has appointed Melanie Margolin to the expanded role of Chief Administrative and Legal Officer. She joined the company as Executive Vice President and Chief Legal Officer in September 2023. Ms. Margolin successfully leverages her experience as a seasoned executive to advance key strategic programs at Clarivate. She has a proven track record of establishing strong controls for complex or ...

Investment Action - Clarivate Plc (NYSE: CLVT) is recommended as a buy due to expected organic growth recovery as the macro environment improves, with no structural weaknesses identified in the business [2] - The organic growth recovery story remains intact, with improvements noted in the two largest segments [2] Earnings Review - In Q2 2024, CLVT reported a revenue decline of 2.8% on a reported basis and 0.6% on an organic basis, with transactional revenue down 4.1% and subscription revenue up 0.7% year-over-year [3] - EBITDA margin contracted by 40bps to 42.2%, but EPS exceeded consensus expectations at $0.20 compared to $0.18 [3] - Organic growth improved from -1.7% in Q1 2024 to -0.6% in Q2 2024, driven by the Academia & Government (A&G) and Intellectual Property (IP) segments [3] Segment Performance - A&G segment organic growth accelerated from 0.6% in Q1 2024 to 1.3% in Q2 2024, with subscription revenue growing over 3% and renewal rates exceeding 96% [3] - IP segment organic growth improved from -4.5% in Q1 2024 to -1.8% in Q2 2024, indicating stabilizing trends in trademark search volumes [3] - Life Sciences & Healthcare (LS&H) segment saw a decline in organic growth from 2.8% to 3.9%, attributed to a weak macro environment affecting large pharma budgets [5] Market Outlook - The long-term trend indicates that R&D expenditure typically increases over time, suggesting a potential recovery following the current macro downturn [5] - Expectations for a strong recovery in the LS&H segment by FY25 as pharma companies resume R&D initiatives [5] Valuation - Current valuation at 6.5x forward PE is considered cheap, with potential upside if growth accelerates to 3% by FY26 and margins improve to 22% [7] - Historical margins ranged between 23-25% from FY20 to FY23, with a target of 22% by FY26 [9] Key Takeaways - A&G segment is expected to return to historical low single-digit growth rates as the macro environment improves [8] - IP segment is likely to continue its organic growth improvement as CLVT gains market share [8] - Recovery timing for the LS&H segment is contingent on macroeconomic recovery, anticipated by FY25 [8]

LONDON, Aug. 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Jonathan Collins, Executive Vice President and Chief Financial Officer, will present at the Oppenheimer 27th Annual Technology, Internet & Communications Virtual Conference, on Monday, August 12, 2024 at 2:55 pm Eastern Time. The live webcast can be accessed at https://wsw.com/webcast/oppenheimer37/clvt/2805750 and will be available for replay. A replay of each webc ...

Group 1 - Clarivate Plc, a leading global provider of transformative intelligence, will have its Executive Vice President and Chief Financial Officer, Jonathan Collins, present at the Oppenheimer 27th Annual Technology, Internet & Communications Virtual Conference on August 12, 2024 [1] - The live webcast of the presentation can be accessed online and will be available for replay [1][2] - Clarivate offers enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare [3]

Clarivate Plc (NYSE:CLVT) Q2 2024 Earnings Conference Call August 6, 2024 9:00 AM ET Company Participants Mark Donohue - Vice President of Investor Relations Andrew Snyder - Chairman of the Board Jonathan Gear - Chief Executive Officer, Matti Shem Tov - Jonathan Collins - Chief Financial Officer Conference Call Participants Toni Kaplan - Morgan Stanley Manav Patnaik - Barclays Surinder Thind - Jefferies Shlomo Rosenbaum - Stifel Wahid Amin - Bank of America Owen Lau - Oppenheimer Andrew Nicholas - William ...

Core Insights - Clarivate PLC (CLVT) reported revenue of $650.3 million for the quarter ended June 2024, reflecting a year-over-year decline of 2.8% and an EPS of $0.20, down from $0.21 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $653.29 million by 0.46%, while the EPS exceeded the consensus estimate of $0.18 by 11.11% [1] Revenue Breakdown - Intellectual Property revenues were $201.60 million, surpassing the average estimate of $199.95 million, but showing a year-over-year decline of 6.8% [3] - Life Sciences & Healthcare revenues totaled $104.20 million, below the average estimate of $107.80 million, marking a year-over-year decrease of 5.7% [4] - Academia & Government revenues reached $344.50 million, exceeding the average estimate of $336.67 million, with a slight year-over-year increase of 0.7% [5] - Transactional and other revenues amounted to $136.10 million, surpassing the average estimate of $120.74 million, but reflecting a year-over-year decline of 10.3% [6] - Re-occurring revenues were reported at $108.60 million, below the average estimate of $111.58 million, indicating a year-over-year decrease of 2.2% [7] - Subscription revenues were $405.60 million, falling short of the average estimate of $420.73 million, with a minimal year-over-year change of -0.1% [8] Stock Performance - Clarivate's shares have returned +9.6% over the past month, contrasting with the Zacks S&P 500 composite's decline of -6.7% [8] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [8]

Clarivate PLC (CLVT) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.21 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 11.11%. A quarter ago, it was expected that this company would post earnings of $0.14 per share when it actually produced earnings of $0.14, delivering no surprise. Over the last four quarters, the company has surpa ...